Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Asthma Allergy ; 17: 733-742, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39131602

RESUMEN

Introduction: Aeroallergen exposure has an intra- and extra-domiciliary component and varies according to climatological zones. Mexico is a large country with a great variety of climates. A previous study (2009) evaluated skin prick test results (SPT) in different regions. In this study, we compare previous sensitization patterns from 14y ago with current ones and compare them between different climatological zones. Methods: Mexican allergists were asked to share their last 100 SPT results in patients with respiratory allergy. Clinics were grouped in (semi)humid vs (semi)dry zones. Results were analyzed nationwide and compared to the 2009 results, calculating odds ratio (OR) and 95% confidence intervals (95% CIs), with p <0.05 as cut-off. Similarly, we compared (semi)humid versus dry zones. Results: We collected 2915 SPT results from 28 clinics (19 cities). Dermatophagoides was the most frequently sensitizing allergen. There was a significant increase in SPT positivity from 2009 to 2023 in both in- and outdoor aeroallergens (OR 1.26-2.65, 95% CI from 1.06-1.50 to 1.99-3.52). Comparing dry-humid zones, sensitization to pollen from Oleaceae, Fagaceae (p < 0.0001 all) and most weeds is more frequent in humid zones, as are Dermatophagoides and cockroach (both p < 0.0001). Eucalyptus, mesquite, and all grass pollen sensitizations predominate in dry zones (p < 0.05-0.0001). There are no differences in sensitization to cat or dog between zones. Conclusion: We found a general increase in SPT sensitization over the past fourteen years, suggesting that this is probably not only due to climate change. The different sensitization profile throughout the country was mainly related to humidity. Repeating epidemiologic SPT studies over the years could help tracking changes in allergen sensitization over time.

2.
Rev Alerg Mex ; 66(2): 263-268, 2019.
Artículo en Español | MEDLINE | ID: mdl-31200425

RESUMEN

Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the "Allergy Diary" on the physician's computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used.


Aunque existen guías clínicas de alta calidad sobre rinitis alérgica, numerosos pacientes reciben tratamiento deficiente, en parte debido al alto grado de automedicación. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS; en ella, los pacientes indican diariamente cuánto les molestan los síntomas a través de cinco pantallas con una escala visual análoga; recientemente se agregaron dos pantallas más (afectación del sueño). La aplicación también permite descargar los datos del "Diario de alergias" en la computadora del médico en el momento de la consulta a través de un código QR. En este artículo reseñamos el primer año de experiencia en España, México y Argentina, que utilizan la versión española.


Asunto(s)
Asma , Aplicaciones Móviles , Rinitis Alérgica , Argentina , Asma/diagnóstico , Asma/terapia , Humanos , Lenguaje , México , Rinitis Alérgica/diagnóstico , Rinitis Alérgica/terapia , España
3.
Rev Alerg Mex ; 66(1): 140-146, 2019.
Artículo en Español | MEDLINE | ID: mdl-31013416

RESUMEN

The vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union against chronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient's cell phone, it first requests some information about the patient's profile, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work / school. After analyzing the data generated by filling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries.


La mayoría de los pacientes con rinitis alérgica no recibe el manejo idóneo, sino que se automedica. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS. Al descargarla al celular del paciente, a este se le piden datos de su perfil, patologías alérgicas y medicación; posteriormente, mediante una escala visual analógica se le invita a determinar el grado de afectación en nariz, ojos y bronquios y su influencia sobre su productividad laboral/escolar. Con los datos del Diario de Alergia se observa que existe un nuevo patrón de presentación: rinitis alérgica + conjuntivitis alérgica + asma, con mayor afectación, así como un alto nivel de automedicación: en general, el paciente toma medicación cuando presenta síntomas. La app se ha desplegado en 23 países, incluyendo varios países hispanohablantes.


Asunto(s)
Asma/tratamiento farmacológico , Conjuntivitis Alérgica/tratamiento farmacológico , Aplicaciones Móviles , Rinitis Alérgica/tratamiento farmacológico , Asma/complicaciones , Conjuntivitis Alérgica/complicaciones , Humanos , Multimorbilidad , Rinitis Alérgica/complicaciones , Automedicación
4.
Rev Alerg Mex ; 66(4): 409-425, 2019.
Artículo en Español | MEDLINE | ID: mdl-32105425

RESUMEN

The health and economic impact of allergic diseases are increasing rapidly, and changes in management strategies are required. Its influence reduces the capacity of work and school performance by at least a third. The ICPs of the airways (integrated care pathways for respiratory diseases) are structured multidisciplinary healthcare plans, promoting the recommendations of the guidelines in local protocols and their application to clinical practice. This document presents an executive summary for Argentina, Mexico, and Spain. Next-generation ARIA guidelines are being developed for the pharmacological treatment of allergic rhinitis (AR), using the GRADE-based guidelines for AR, tested with real-life evidence provided by mobile technology with visual analogue scales. It is concluded that in the AR treatment, H1-antihistamines are less effective than intranasal corticosteroids (INCS), in severe AR the INCS represent the first line of treatment, and intranasal combination INCS + anti-H1 is more effective than monotherapy. However, according to the MASK real-life observational study, patients have poor adherence to treatment and often self-medicate, according to their needs.


El impacto sanitario y económico de las enfermedades alérgicas está aumentando rápidamente y se necesitan cambios en las estrategias para su manejo. Su influencia reduce al menos en un tercio la capacidad de desempeño laboral y escolar. Los ICP (Vías Integradas de Atención) de las enfermedades de las vías respiratorias son planes de atención estructurados y multidisciplinarios, que promueven las recomendaciones de las guías en protocolos locales y su aplicación a la práctica clínica. En este documento se presenta un resumen ejecutivo para Argentina, México y España. Se desarrollan las guías ARIA de próxima generación para el tratamiento farmacológico de la rinitis alérgica (RA) utilizando las pautas basadas en GRADE para RA, probadas con evidencia de la vida real proporcionada por tecnología móvil basada en escalas visuales analógicas. Se concluye que en el tratamiento de la RA, los antihistamínicos anti-H1 son menos efectivos que los corticoides intranasales (CINS), que en la rinitis gravelos CINS representan la primera línea de tratamiento, y que la combinación intranasal de CINS + anti-H1 es más eficaz que la monoterapia. Sin embargo, según el estudio MASK observacional en vida real, los pacientes tienen pobre adherencia al tratamiento y frecuentemente se automedican de acuerdo con sus necesidades.


Asunto(s)
Prestación Integrada de Atención de Salud , Rinitis Alérgica/terapia , Algoritmos , Argentina , Vías Clínicas , Humanos , México , España
5.
Int Arch Allergy Immunol ; 163(4): 252-8, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24713632

RESUMEN

BACKGROUND: Restrictive, very low-energy diets focused on rapid weight loss have proven to be effective in improving asthma outcome in obese patients, but their use in children and pubescents is controversial due its potential consequences in growth. More conservative, normocaloric schemes are suggested as a more suitable dietary approach for these patients. METHODS: A randomized clinical trial was run of 51 pubertal adolescents with asthma and obesity, who were allocated to either an interventional 28-week program of normocaloric diet based on normal requirements for height and meal planning (n = 26) or a non-interventional (free diet) control group (n = 25). Asthma-related quality of life (AR-QOL, assessed by the Standardized Pediatric Asthma Quality of Life Questionnaire, PAQLQ[S]) and clinical indicators of asthma control were measured before and after the intervention period. RESULTS: Diet intervention was associated with a significant improvement in AR-QOL in relation to baseline (Δ PAQLQ[S] scores) compared with controls, both in overall score (p < 0.001) and its subdomains (activity limitation, p < 0.001; symptoms, p < 0.002; emotional function, p < 0.001). The group with normocaloric diet observed a significant decrease in body mass index z-score, which correlated positively with the improvement in AR-QOL (Spearman's r = 0.51, p < 0.01), in addition to have significantly fewer events of acute attacks of asthma and nighttime awakenings, plus a non-significant reduction in the use of inhaled corticosteroids. No significant changes were observed in the pulmonary function tests. CONCLUSION: The normocaloric dietary intervention was associated with improvement of AR-QOL and some aspects of asthma control. Such structured dietary programs could probably have a role as a complementary non-pharmacological therapeutic strategy in obese pubertal adolescents with asthma.


Asunto(s)
Asma/dietoterapia , Dieta Reductora , Obesidad Infantil/dietoterapia , Calidad de Vida , Adolescente , Índice de Masa Corporal , Niño , Terapias Complementarias , Conducta Alimentaria , Femenino , Humanos , Masculino , Cooperación del Paciente , Encuestas y Cuestionarios , Pérdida de Peso
6.
Rev Alerg Mex ; 53(5): 179-82, 2006.
Artículo en Español | MEDLINE | ID: mdl-17357564

RESUMEN

BACKGROUND: Drug adverse reactions are a common cause of morbidity and they constitute an important challenge in medical practice. The allergic reactions represent only a small proportion of all the drug adverse reactions and although their real prevalence is unknown, some estimated numbers have been suggested. It seems that atopia is not a risk factor for the development of this kind of reactions. PATIENTS AND METHODS: A cross-sectional descriptive study was performed to assess the prevalence of drug allergy in asthmatic children of the northeast of Mexico that attend summer camps. We investigated the history of drug adverse reactions and their clinical features in 90 atopic asthmatic patients from 5 to 15 years old which were evaluated trough a questionnaire that was completed by their parents. RESULTS: Eight of the 90 evaluated patients (8.8%) had history of adverse reactions to some drug. The drugs involved in that reactions were: penicillin in four patients (50%), aspirin in 2 (25%), trimethoprim and sulfamethoxazole in one (12.5%) and metamizole sodium in one (12.5%). The most common administration route was oral. In all of the cases the diagnosis was made on clinical basis. One of the patients had suffered from anaphylaxis, but in the other seven, urticaria was the unique clinical manifestation of the reaction. In all of the affected patients, the reactions were totally resolved in less than 48 hours. CONCLUSIONS: The prevalence of drug allergy in this group was similar to that reported in general population. Penicillin was the most common involved drug and urticaria was the most frequent clinical manifestation.


Asunto(s)
Asma/epidemiología , Hipersensibilidad a las Drogas/epidemiología , Adolescente , Anafilaxia/epidemiología , Anafilaxia/etiología , Aspirina/efectos adversos , Niño , Preescolar , Comorbilidad , Estudios Transversales , Erupciones por Medicamentos/epidemiología , Erupciones por Medicamentos/etiología , Hipersensibilidad a las Drogas/etiología , Femenino , Humanos , Hipersensibilidad Inmediata/epidemiología , Masculino , Metimazol/efectos adversos , México/epidemiología , Penicilinas/efectos adversos , Prevalencia , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Urticaria/inducido químicamente , Urticaria/epidemiología
7.
Rev Alerg Mex ; 53(5): 189-93, 2006.
Artículo en Español | MEDLINE | ID: mdl-17357566

RESUMEN

Hereditary angioedema is an uncommon disorder mainly caused by defects of the gene for C1 inhibitor. These patients present recurrent edema episodes in the different regions of the body, including larynx edema in some cases. Low plasma levels of C1 inhibitor confirm the diagnosis. It is important to establish an early diagnosis and prompt treatment to this disorder due to its potential of fatal consequences and multiple alterations in the quality of life that have been associated with. The indicated treatment is substitutive therapy of C1 inhibitor concentrate. We present the case of a patient a 27 year-old female with a history of seven years of evolution, with daily periorbital, upper and lower extremities and labial edema episodes who was classified as C1 inhibitor deficiency type II. She began treatment with attenuated androgens in progressive increased doses with poor response, appearing torpid evolution without a favorable response. This case corresponds to a very atypical presentation of C1 inhibitor deficiency with daily symptoms, unlike the typical intermittent course of the classic disease.


Asunto(s)
Angioedema/genética , Proteína Inhibidora del Complemento C1/genética , Dolor Abdominal/etiología , Adulto , Angioedema/complicaciones , Angioedema/diagnóstico , Angioedema/inmunología , Antialérgicos/uso terapéutico , Enfermedad Crónica , Proteína Inhibidora del Complemento C1/análisis , Complemento C4/deficiencia , Danazol/efectos adversos , Danazol/uso terapéutico , Resistencia a Medicamentos , Párpados/patología , Dermatosis Facial/genética , Dermatosis Facial/inmunología , Femenino , Gastritis/complicaciones , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Humanos , Fenotipo , Virilismo/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA